Clinical Trials
- Sarcoma Cancers, Kidney Cancer, Pediatric Cancers
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumors
- Sarcoma Cancers
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
- Ages18 years and older
- GenderBoth
- Sarcoma Cancers, Cancer
A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients With High Risk RetroPeritoneal Sarcoma (RPS)
- Ages18 years and older
- GenderBoth
- Sarcoma Cancers, Brain and Other Nervous System Cancers, Leukemia
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
- Ages1 year - 21 years
- GenderBoth
- Sarcoma Cancers, Brain and Other Nervous System Cancers, Other Cancers, Lymphoma, Kidney Cancer, Leukemia, Liver Cancer, Stomach and Esophagus, Thyroid and Other Endocrine Cancers, Gynecological Cancers, Lung Cancer, Bladder Cancer, Colorectal Cancer, Pediatric Cancers
The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
- Colorectal Cancer, Head and Neck Cancers, Lung Cancer, Melanoma, Gynecological Cancers
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Stomach and Esophagus, Head and Neck Cancers
A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA
- Head and Neck Cancers
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers
- Head and Neck Cancers
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
- Head and Neck Cancers
Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab in Patients With Selected Resectable Tumors
- Ages18 years and older
- GenderBoth